Supplementary Figure S9 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Ilango Balakrishnan; Krishna Madhavan; Angela Pierce; Joshua Michlin; Breauna Brunt; Senthilnath Lakshmanachetty; Dong Wang; John DeSisto; Zachary James Nuss; Nathan Davidson; Faye Walker; Ammu Suresh; Andrew M. Donson; Bridget Sanford; Kenneth L. Jones; Etienne Danis; Siddhartha S. Mitra; Adam L. Green; Nathan Dahl; Rajeev Vibhakar; Sujatha Venkataraman

doi:10.1158/0008-5472.29918843

Key Points

Blocking cd99 with 10D1 and ffRT significantly reduces tumor burden in diffuse midline glioma, improving patient outcomes.
Increased body weight observed, suggesting potential benefits of treatment without apparent toxicity.
Flow cytometry and western blotting confirmed elevated cd99 levels, supporting the study's findings regarding the antibody's efficacy.
CBC analysis indicated no significant adverse effects, highlighting the safety of this treatment protocol.

Implication

Observational analysis shows reduced tumor burden in diffuse midline glioma using anti-CD99 antibody and FFRT, indicating enhanced therapeutic effects.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Balakrishnan et al. (2025) studied this question.

synapsesocial.com/papers/68af56faad7bf08b1eadd1aa https://doi.org/10.1158/0008-5472.29918843

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S9 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S9 from Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers